Arvinas Management
Management criteria checks 2/4
Arvinas' CEO is John Houston, appointed in Sep 2017, has a tenure of 6.75 years. total yearly compensation is $7.63M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth $22.40M. The average tenure of the management team and the board of directors is 1 years and 4.7 years respectively.
Key information
John Houston
Chief executive officer
US$7.6m
Total compensation
CEO salary percentage | 8.6% |
CEO tenure | 6.8yrs |
CEO ownership | 1.3% |
Management average tenure | less than a year |
Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
Jun 27Arvinas: Behind The Huge Rally
Mar 03What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Feb 25News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Aug 13There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price
May 05Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)
Feb 24Arvinas initiated Overweight at Barclays on attractive therapeutic platform
Sep 09Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Aug 19Arvinas: Still Holding, Just Not Buying More
May 23Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma
Feb 07CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$355m |
Dec 31 2023 | US$8m | US$658k | -US$367m |
Sep 30 2023 | n/a | n/a | -US$295m |
Jun 30 2023 | n/a | n/a | -US$298m |
Mar 31 2023 | n/a | n/a | -US$301m |
Dec 31 2022 | US$10m | US$632k | -US$282m |
Sep 30 2022 | n/a | n/a | -US$253m |
Jun 30 2022 | n/a | n/a | -US$233m |
Mar 31 2022 | n/a | n/a | -US$213m |
Dec 31 2021 | US$13m | US$584k | -US$191m |
Sep 30 2021 | n/a | n/a | -US$180m |
Jun 30 2021 | n/a | n/a | -US$164m |
Mar 31 2021 | n/a | n/a | -US$139m |
Dec 31 2020 | US$8m | US$564k | -US$119m |
Sep 30 2020 | n/a | n/a | -US$99m |
Jun 30 2020 | n/a | n/a | -US$86m |
Mar 31 2020 | n/a | n/a | -US$78m |
Dec 31 2019 | US$5m | US$528k | -US$70m |
Sep 30 2019 | n/a | n/a | -US$65m |
Jun 30 2019 | n/a | n/a | -US$173m |
Mar 31 2019 | n/a | n/a | -US$179m |
Dec 31 2018 | US$6m | US$428k | -US$240m |
Sep 30 2018 | n/a | n/a | -US$233m |
Jun 30 2018 | n/a | n/a | -US$114m |
Mar 31 2018 | n/a | n/a | -US$98m |
Dec 31 2017 | US$954k | US$371k | -US$29m |
Compensation vs Market: John's total compensation ($USD7.63M) is above average for companies of similar size in the US market ($USD5.68M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Houston (64 yo)
6.8yrs
Tenure
US$7,627,032
Compensation
Dr. John G. Houston, Ph.D. serves as Independent Director at NextCure, Inc. since September 10, 2020. He has been President, Chief Executive Officer and Director of Arvinas, Inc. since September 20, 2017 a...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairperson | 6.8yrs | US$7.63m | 1.27% $ 22.4m | |
President of Research & Development and Chairman of Scientific Advisory Board | no data | US$2.73m | 0.14% $ 2.4m | |
CFO & Treasurer | no data | no data | no data | |
VP, Chief Accounting Officer & Corporate Controller | 1.5yrs | no data | no data | |
Chief Scientific Officer | no data | no data | 0.018% $ 311.9k | |
Vice President of Investor Relations | 3.4yrs | no data | no data | |
General Counsel & Corporate Secretary | less than a year | no data | no data | |
Senior VP & Chief Human Resources Officer | no data | no data | no data | |
Senior Vice President of R&D Technical Operations | no data | no data | no data | |
Chief Business Officer | less than a year | no data | 0.021% $ 368.8k | |
Chief Commercial Officer | 1.8yrs | no data | no data | |
Senior Vice President of Corporate Operations | 1.8yrs | no data | no data |
1.0yrs
Average Tenure
55yo
Average Age
Experienced Management: ARVN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairperson | 6.8yrs | US$7.63m | 1.27% $ 22.4m | |
President of Research & Development and Chairman of Scientific Advisory Board | no data | US$2.73m | 0.14% $ 2.4m | |
Independent Director | 5.9yrs | US$422.69k | 0.068% $ 1.2m | |
Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
Independent Director | 4.9yrs | US$424.99k | 0.0060% $ 106.6k | |
Lead Independent Director | 6yrs | US$441.76k | 0.035% $ 623.3k | |
Independent Director | 4.6yrs | US$430.30k | 0.0060% $ 106.6k | |
Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
Member of Scientific Advisory Board | 4.7yrs | no data | no data | |
Independent Director | 1.8yrs | US$422.49k | 0.0060% $ 106.6k | |
Independent Director | 4yrs | US$434.99k | 0.0060% $ 106.6k |
4.7yrs
Average Tenure
62yo
Average Age
Experienced Board: ARVN's board of directors are considered experienced (4.7 years average tenure).